Gonadatropins Patents (Class 530/398)
  • Publication number: 20150148291
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Inventors: UDI EYAL FIMA, GILI HART
  • Publication number: 20150141331
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 21, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Fuad FARES, Udi Eyal Fima
  • Publication number: 20150126445
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Publication number: 20150126444
    Abstract: CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Patent number: 8999670
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: April 7, 2015
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Publication number: 20150093358
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.
    Type: Application
    Filed: November 26, 2014
    Publication date: April 2, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Patent number: 8993732
    Abstract: The present invention, pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: March 31, 2015
    Assignee: Ferring B.V.
    Inventors: Helen Ulrika Sjögren, Heidi Louise Bagger
  • Publication number: 20150065695
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: November 14, 2014
    Publication date: March 5, 2015
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 8962558
    Abstract: A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: February 24, 2015
    Inventor: Johannes C. Van Groeninghen
  • Patent number: 8951967
    Abstract: The present disclosure describes recombinant follicle stimulating hormone (FSH) and methods for the production thereof. The recombinant FSH can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant FSH can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: February 10, 2015
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 8940876
    Abstract: The present disclosure relates to a method for preparing recombinant glycoproteins with high sialic acid content. More specifically, for UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK) enzyme where point mutation was induced by substituting arginine at position 263 by leucine only or by further substituting arginine at position 266 by glutamine, epimerase activity is constantly maintained, and overexpressed cells thereof experience an increase in intracellular cytidine monophosphate (CMP)-sialic acid content, irrespective of CMP-sialic acid concentration.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: January 27, 2015
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Jung Hoe Kim, Young Dok Son, Jin Young Hwang, Yeon Tae Jeong
  • Publication number: 20140371146
    Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • Patent number: 8877902
    Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: November 4, 2014
    Assignee: Red Mountain Med Spa, LLC
    Inventors: Mark Bentz, Suzanne Bentz, Riccardo Roscetti, M. Socorro Parra Arenas
  • Publication number: 20140316112
    Abstract: This invention is directed to the use of a chorionic gonadotrophin carboxy terminal peptide (CTP) or fragments thereof for modifying a polypeptide or a fragment thereof in order to increase the hydrodynamic volume of the polypeptide or fragment thereof.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 23, 2014
    Inventors: Oren HERSHKOVITZ, Ahuva BAR-ILAN
  • Patent number: 8846344
    Abstract: The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 30, 2014
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Lars Stockl
  • Patent number: 8835386
    Abstract: The present invention provides methods of producing biologically active recombinant eFSH analogs and methods of increasing reproduction in mammals, particularly equine, using recombinant eFSH analogs. Also provided are methods of producing biologically active single chain recombinant eFSH. The recombinant eFSH analogs of the present invention increase superovulation, follicular development, embryo development, and reproductive efficiency in horses, cattle and other ungulates.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: September 16, 2014
    Assignees: Venaxis, Inc., Washington University, The Regents of the University of California
    Inventors: Mark Colgin, Kory Niswender, Irving Boime, Janet Roser
  • Publication number: 20140249082
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 4, 2014
    Applicant: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20140212897
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • Publication number: 20140088010
    Abstract: Preparations including poly (ethylene glycol) modified recombinant hCG(rhCG).
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicant: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov
  • Patent number: 8664369
    Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: March 4, 2014
    Assignee: Merck Serono S.A.
    Inventors: Rita Agostinetto, Fabrizio Samaritani, Alessandra Del Rio, Joel Richard
  • Publication number: 20140031530
    Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Application
    Filed: July 30, 2013
    Publication date: January 30, 2014
    Applicant: Trophogen Inc.
    Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
  • Patent number: 8604175
    Abstract: The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant, comprising the steps of subjecting a liquid containing FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a strong anion exchange chromatography; which may be carried out in any order.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: December 10, 2013
    Assignee: Ares Trading S.A.
    Inventors: Thierry Ziegler, Mara Rossi, Antonello Datola, Sabrina Fiumi
  • Patent number: 8603974
    Abstract: This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: December 10, 2013
    Inventor: William R. Moyle
  • Publication number: 20130303451
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Application
    Filed: April 22, 2013
    Publication date: November 14, 2013
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Patent number: 8541245
    Abstract: The present invention provides methods and kits for assessing the state of oocyte maturation in a female mammal based on the level of PAPP-A found in the female's bodily fluid sample.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: September 24, 2013
    Assignee: Beckman Coulter, Inc.
    Inventor: William E. Roudebush
  • Patent number: 8530190
    Abstract: The invention relates to analogs of glycoprotein hormones with an intersubunit disulfide crosslink and their preparation and use. Corresponding DNA sequences and host cells, as well as pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: September 10, 2013
    Assignee: Merck Serono SA
    Inventor: William R. Moyle
  • Patent number: 8518881
    Abstract: The present invention provides methods of producing biologically active recombinant bFSH and methods of increasing reproduction in mammals, particularly bovine, using recombinant bFSH. Also provided are methods of producing single chain recombinant bFSH. The recombinant bFSH of the present invention increases superovulation, embryo development, and reproductive efficiency in cattle and other ungulates.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: August 27, 2013
    Assignee: AspenBio Pharma, Inc.
    Inventors: Mark A. Colgin, Richard G. Donnelly, Brad Stroud
  • Patent number: 8476234
    Abstract: Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 2, 2013
    Assignee: Prolor Biotech Inc.
    Inventors: Udi Eyal Fima, Gili Hart
  • Publication number: 20130137636
    Abstract: The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.
    Type: Application
    Filed: August 4, 2011
    Publication date: May 30, 2013
    Applicant: GLYCOTOPE GMBH
    Inventors: Steffen Goletz, Lars Stockl
  • Patent number: 8450269
    Abstract: Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: May 28, 2013
    Assignee: Prolor Biotech Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 8377879
    Abstract: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2013
    Assignee: Trophogen, Inc.
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • Publication number: 20130034547
    Abstract: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 ? of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 ? of each other. That sequon is absent from the pre-existing therapeutic polypeptide.
    Type: Application
    Filed: August 2, 2012
    Publication date: February 7, 2013
    Inventors: Jeffery W. Kelly, Joshua L. Price, Elizabeth K. Culyba, Evan T. Powers
  • Publication number: 20130023476
    Abstract: Preparations including recombinant hCG (r hCG).
    Type: Application
    Filed: October 4, 2010
    Publication date: January 24, 2013
    Applicant: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Publication number: 20120252069
    Abstract: The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.
    Type: Application
    Filed: November 24, 2010
    Publication date: October 4, 2012
    Applicant: GLYCOTOPE GmbH
    Inventors: Steffen Goletz, Lars Stockl
  • Publication number: 20120149874
    Abstract: The present disclosure relates to a method for preparing recombinant glycoproteins with high sialic acid content. More specifically, for UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK) enzyme where point mutation was induced by substituting arginine at position 263 by leucine only or by further substituting arginine at position 266 by glutamine, epimerase activity is constantly maintained, and overexpressed cells thereof experience an increase in intracellular cytidine monophosphate (CMP)-sialic acid content, irrespective of CMP-sialic acid concentration.
    Type: Application
    Filed: February 1, 2011
    Publication date: June 14, 2012
    Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jung Hoe Kim, Young Dok Son, Jin Young Hwang, Yeon Tae Jeong
  • Publication number: 20120135928
    Abstract: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or re-combinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.
    Type: Application
    Filed: April 1, 2010
    Publication date: May 31, 2012
    Applicant: BIOGENERIX AG
    Inventors: Christian Scheckermann, Dietmar Eichinger, Stefan Arnold
  • Publication number: 20120094356
    Abstract: The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
    Type: Application
    Filed: April 22, 2010
    Publication date: April 19, 2012
    Applicant: ALTEOGEN, INC.
    Inventors: Hye-Shin Chung, Seung Bum Yoo, Sang Mee Lee
  • Publication number: 20120059145
    Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventor: Elliot ALTMAN
  • Patent number: 8106158
    Abstract: The present invention relates to compositions and methods for fusion protein separation utilizing a peptide linker comprising a novel thrombin cleavage site.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: January 31, 2012
    Assignee: ViroMed Co., Ltd.
    Inventors: Sujeong Kim, Jong-Mook Kim, Song Shan Xu
  • Publication number: 20120021984
    Abstract: This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region.
    Type: Application
    Filed: May 24, 2011
    Publication date: January 26, 2012
    Applicant: University of Medicine and Dentistry of New Jersey
    Inventor: William R. Moyle
  • Patent number: 8093052
    Abstract: The present invention is in the field of the manufacture of recombinant proteins. More specifically, it relates to the use of a serum-free culture medium comprising an antioxidant for the production of recombinant dimeric gonadotropins. The antioxidant may be selected from the group consisting of L-glutathione, 2-mercaptoethanol, L-methionine and a combination of ascorbic acid and of (+)-alpha-tocoplierol.
    Type: Grant
    Filed: July 4, 2006
    Date of Patent: January 10, 2012
    Assignee: Ares Trading S.A.
    Inventors: Jean-Pierre Fonta, Paul Ducommun, Véronique Deparis
  • Publication number: 20110319590
    Abstract: The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of the present invention. In another aspect the present invention relates to methods for producing the aforementioned compositions.
    Type: Application
    Filed: August 11, 2011
    Publication date: December 29, 2011
    Applicant: GLYCOTOPE GmbH
    Inventors: Steffen Goletz, Hans Baumeister, Marion Schlangstedt, Ute SCHÖBER
  • Patent number: 8048849
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: November 1, 2011
    Assignee: Modigene, Inc.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Publication number: 20110263500
    Abstract: Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma.
    Type: Application
    Filed: September 16, 2009
    Publication date: October 27, 2011
    Inventors: William Hansel, Sita Aggarwal, Robert P. Hammer
  • Patent number: 8044187
    Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the ?-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the ?-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: October 25, 2011
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann
  • Patent number: 7985732
    Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: July 26, 2011
    Assignee: Ferring B.V.
    Inventor: Marco Filicori
  • Patent number: 7964562
    Abstract: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the treatment regimen and accommodate different therapeutic goals as well as individual patient responses to gonadotropin administration.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: June 21, 2011
    Assignee: Ferring B.V.
    Inventor: Marco Filicori
  • Patent number: 7956034
    Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: June 7, 2011
    Assignee: Merck Serono SA
    Inventors: Marco Muda, Xuliang Jiang, Sean D. McKenna
  • Publication number: 20110105379
    Abstract: Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed.
    Type: Application
    Filed: August 20, 2008
    Publication date: May 5, 2011
    Applicant: Protalix Ltd.
    Inventors: Avidor Shulman, Ilya Ruderfer
  • Publication number: 20110105398
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: April 16, 2009
    Publication date: May 5, 2011
    Applicant: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White